Resources
About Us
Home Report
Store
NGS Market: Industry Outlook
Next-Generation Sequencing (NGS) Market: Industry Outlook by Offering (Sample Preparation [DNA Extraction, Library Preparation, Automation], Systems, Bioinformatics, Sequencing Services) Application (Clinical, Research) End User — Global Forecast to 2031
Report ID:MRHC - 1041274 Pages: 451 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursNext-Generation Sequencing (NGS) Market Size & Forecast
The NGS Market is projected to reach $42.7 billion by 2031 at a CAGR of 15.7% from 2024 to 2031. The growth of the NGS market is driven by the rising cancer prevalence & the increasing application of NGS in cancer treatment and research, partnerships between NGS service providers & pharmaceutical companies, technological advancements in NGS, the growing demand for optimized & streamlined NGS workflows, the declining costs of genome sequencing, technological advancements in sequencing procedures, technological advancements in NGS informatics solutions, increasing pharmaceutical R&D expenditures, the surge in genome mapping programs, and improvements in regulatory & reimbursement scenarios for NGS-based diagnostic tests.
Furthermore, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, collaborations between vendors to develop library preparation protocols, the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation, the increasing adoption of NGS informatics tools among hospitals and clinical laboratories, and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the players operating in the NGS market.
NGS Market Growth Drivers
Rising Cancer Prevalence & Increasing Application of NGS in Cancer Treatment and Research
Cancer is a major cause of death and a prominent obstacle in improving life expectancy globally. According to GLOBOCAN, the number of new cancer cases is expected to increase from 19.2 million in 2020 to 24.5 million in 2030. In addition, mortalities from cancer are expected to increase from 9.9 million in 2020 to 12.9 million in 2030. Thus, the increasing prevalence of cancer is expected to boost the adoption of NGS in clinical settings. Next-generation Sequencing (NGS) is considerably contributing to researchers’ understanding of cancer biology. Genomics research supported by NGS has identified genetic heterogeneity even among cancer types that were earlier considered identical. The discovery of unique molecular signatures is helping in the development of potential cancer treatments, increasing the demand for NGS in cancer research.
Click here to: Get Free Sample Pages of this Report
Technological Advancements in NGS Informatics Solutions
The need for genomic data drives the demand for next-generation sequencing. The huge volumes of data generated from NGS have created enormous pressure on healthcare providers in terms of data analysis, interpretation, reporting, and management. Data storage and computing tools save money and time while scaling production, keep data secure with monitoring by security and compliance, and easily share volumes of genomic data in multiple working groups with user and team-specific access.
Technological advancements in NGS informatics solutions have made it easier to create long sequencing runs, analyze sequencing data, monitor run status, and view results within shorter timeframes. Additionally, data flow from instruments can now be processed by software, making it easier to manage and analyze data using data analysis applications. NGS informatics technology has allowed the discovery of genetically targeted drugs and blood tests to detect cancer early. It has also enabled diagnoses for people with rare diseases. Thus, the technological advancements in NGS informatics solutions are expected to drive the growth of the NGS market.
NGS Market Restraints
Availability of Alternative Technologies
Cheaper and well-established alternatives to next-generation sequencing (NGS) for cell molecular profiling, such as microarray, Fluorescence In Situ Hybridization (FISH), and Polymerase Chain Reaction (PCR), are readily available. These methods have traditionally been used in cancer cell molecular profiling to detect actionable genetic alterations or biomarkers. Other alternative technologies include Allele-specific array Comparative Genomic Hybridization (aCGH), Sanger dideoxy sequencing, pyrosequencing, Multiplex Ligation-dependent Probe Amplification (MLPA), and Mass Spectrometry (MS) for gene studies. Therefore, the availability of these alternative technologies restrain the adoption of NGS, impeding the growth of the NGS market.
NGS Market Opportunity
Increasing Application of NGS in Personalized Medicine
Precision medicine is an emerging approach to patient care. Physicians choose a treatment method based on the patient’s genetic makeup, also considering genetic changes resulting from a disease and lifestyle habits. It is an emerging disease treatment & prevention approach that considers variability in genes, environments, and lifestyles among individuals. Precision medicine can reduce the need for guesswork (trial and error in medication depending on how the medication affects the patient’s symptoms), help physicians overcome challenges related to variable diagnostic ability, and aid the development of treatment strategies based on generalized demographics. Moreover, precision medicine provides a more holistic view of an individual’s health. In clinical workflows, precision medicine facilitates more predictive and preventive care through targeted therapies. Thus, the use of NGS in precision medicine to enable more personalized approaches is expected to create market growth opportunities.
Rising Adoption of Bioinformatics and Genomic Data Management Solutions
NGS bioinformatics solutions offer additional features, such as data security and accuracy, by converting sequencing information into a standard format. This allows for the monitoring of instrument run quality and the streaming of data directly to on-premises or cloud servers. Moreover, benefits such as access to computing resources with minimum in-house infrastructure and increased efficiency with easy access to a multitude of genomic analysis applications have significantly increased the adoption of NGS bioinformatics solutions.
NGS Market Analysis: Key Findings
By Offering: In 2024, the Commercial Sequencing/Outsourced Services Segment to Dominate the NGS Market
Based on offering, the NGS market is segmented into commercial sequencing/outsourced services, sample preparation, sequencing, and data analysis/bioinformatics. The commercial sequencing/outsourced services segment is further sub-segmented into targeted sequencing services, whole-genome sequencing services, RNA sequencing services, exome sequencing services, de novo sequencing services, ChIP sequencing services, methyl sequencing services, and other NGS services. In 2024, the commercial sequencing/outsourced services segment is expected to account for the largest share of 38.0% of the NGS market. The large market share of this segment can be attributed to the advantages offered by commercial sequencing/outsourced services, such as rapid delivery of results, access to advanced instruments and trained professionals, and lower costs compared to in-house sequencing.
By Application: In 2024, the Research & Other Applications Segment to Dominate the NGS Market
Based on application, the market is segmented into research & other applications and clinical applications. In 2024, the research & other applications segment is expected to account for the largest share of 62.2% of the NGS market. The large market share of this segment can be attributed to the growing prevalence of genetic disorders, the increasing adoption of sequencing-based tests in laboratories, the growing demand for personalized medicines, and the increase in NGS-based research.
By End User: In 2024, the Pharmaceutical & Biotechnology Companies Segment to Dominate the NGS Market
Based on end user, the NGS market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users. In 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of 43.5% of the NGS market. The large market share of this segment is attributed to the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of chronic diseases, which drive the adoption of next-generation sequencing products among pharmaceutical & biotechnology companies.
Geographical Analysis
In 2024, North America is expected to account for the largest share of 48.7% of the NGS market. North America’s significant market share can be attributed to the increasing R&D expenditures in the pharmaceutical & biotechnology sector, the presence of leading NGS market players in the region, favorable government initiatives for genomics research, growing applications of NGS-based research, rising awareness of NGS-based tests, increasing prevalence of cancer and genetic diseases, and favorable reimbursement scenario in the region.
However, the market in Asia-Pacific is projected to register the highest growth rate of 16.9% during the forecast period. Countries such as China and India are anticipated to offer significant growth opportunities for the vendors in this market. Many Asia-Pacific nations are increasing their efforts to enhance the healthcare sector, leading to increased investments in improving healthcare accessibility, infrastructure, and drug discovery programs. Other key factors driving the growth of this regional market include the increasing incidence of cancer, rising adoption of advanced diagnostic and therapeutic technologies, and government initiatives promoting genome sequencing programs.
NGS Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years. The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute (BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics (U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest Diagnostics Incorporated (U.S.).
NGS Industry Overview: Latest Developments from Key Industry Players
-
In January 2024, Illumina Inc. (U.S.) signed an agreement with Janssen Research & Development, LLC (U.S.). The agreement marks the start of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution for detecting circular tumor DNA (ctDNA) for understanding the recurrence or persistence of disease following clinical intervention.
-
In March 2024, Thermo Fisher Scientific Inc. (U.S.) collaborated with Bayer AG (Germany) to develop NGS-based companion diagnostic assays (CDx) that offer decentralized genomic testing and rapid turnaround time to help increase patient access to Bayer’s precision cancer therapies.
- In January 2024, the QIAGEN Digital Insights (QDI) bioinformatics business of QIAGEN N.V. (Netherlands) launched the QIAGEN CLC Genomics Workbench with premium light technology, which supports next-generation sequencing for somatic cancer.
- In September 2023, Thermo Fisher Scientific Inc. (U.S.) partnered with Pfizer Inc. (U.S.) to expand access to localized NGS-based testing of breast and lung cancer patients in over 30 countries across Africa, Latin America, the Middle East, and Asia, where advanced genomic testing has previously been unavailable or limited.
- In March 2023, Illumina Inc. (U.S.) launched its Connected Insights, a cloud-based software that enables tertiary analysis of clinical NGS data.
NGS Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
451 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
15.7% |
|
Estimated Market Size (Value) |
$42.7 billion by 2031 |
|
Segments Covered |
By Offering
By Application
By End User
|
|
Countries/Regions Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa |
|
Key Companies |
The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute (BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics (U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest Diagnostics Incorporated (U.S.). |
Key questionsanswered in the NGS market report:
The global NGS market report covers the qualitative analysis and sizing of the market based on offering, application, and end user. It provides an analysis of these market segments at the regional and country level. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The global NGS market is projected to reach $42.7 billion by 2031 at a CAGR of 15.7% from 2024 to 2031.
Among the offerings covered in this report, in 2024, the commercial sequencing/outsourced services segment is expected to account for the largest share of the NGS market. The large market share of this segment can be attributed to the advantages offered by commercial sequencing/outsourced services, such as rapid delivery of results, access to advanced instruments and trained professionals, and lower costs compared to in-house sequencing.
Among the applications covered in this report, in 2024, the research & other applications segment is expected to account for the largest share of the NGS market. The large share of the segment is attributed to the decreasing cost of sequencing procedures, increasing R&D by pharmaceutical and biotechnology companies for drug discovery, the increasing applications of NGS in multiple clinical and research settings, and the use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.
The growth of the NGS market is driven by the rising cancer prevalence & the increasing application of NGS in cancer treatment and research, partnerships between NGS service providers & pharmaceutical companies, technological advancements in NGS, the growing demand for optimized & streamlined NGS workflows, the declining costs of genome sequencing, technological advancements in sequencing procedures, technological advancements in NGS informatics solutions, increasing pharmaceutical R&D expenditures, the surge in genome mapping programs, and improvements in regulatory & reimbursement scenarios for NGS-based diagnostic tests.
Furthermore, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, collaborations between vendors to develop library preparation protocols, the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation, the increasing adoption of NGS informatics tools among hospitals and clinical laboratories, and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the players operating in the NGS market.
The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute (BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics (U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest Diagnostics Incorporated (U.S.).
Countries like China and India within Asia-Pacific are poised to offer significant growth opportunities for the vendors in this market. The growth of this regional market is driven by rapid economic growth across many countries, resulting in increased government focus on healthcare improvement. This has led to substantial investments in enhancing healthcare service accessibility, upgrading infrastructure, and fostering drug discovery and genome mapping initiatives.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.1.1. Rising Cancer Prevalence & Increasing Application of NGS in Cancer Treatment and Research Driving Market Growth
4.2.1.2. Availability of Alternative Technologies Restraining Market Growth
4.2.1.3. Increasing Application of NGS in Personalized Medicine Generating Growth Opportunities for Market Players
4.2.1.4. Data Storage, Handling, Interpretation, and Confidentiality Concerns Expected to Remain a Major Challenge for Market Stakeholders
4.2.2. Factor Analysis
4.3. Industry Trends
4.3.1. Increasing Partnerships & Collaborations Among NGS Solution Providers to Expand and Advance Product Offerings
4.3.2. Development of Portable Sequencing Technologies
4.3.3. Increasing Demand for NGS Automation
4.4. Pricing Analysis
4.4.1. NGS Instruments and Consumables
4.4.2. NGS Services
4.5. Regulatory Analysis
4.5.1. NGS Instruments & Consumables
4.5.1.1. North America
4.5.1.1.1. U.S.
4.5.1.1.2. Canada
4.5.1.2. Europe
4.5.1.3. Asia-Pacific
4.5.1.3.1. China
4.5.1.3.2. Japan
4.5.1.3.3. India
4.5.1.4. Latin America
4.5.1.5. Middle East
4.5.2. NGS Informatics
4.6. Case Studies/Use Cases
4.6.1. Case Study A
4.6.2. Case Study B
4.6.3. Case Study C
4.6.4. Case Study D
4.7. Porter’s Five Forces Analysis
4.7.1. Bargaining Power of Buyers
4.7.2. Bargaining Power of Suppliers
4.7.3. Threat of Substitutes
4.7.4. Threat of New Entrants
4.7.5. Degree of Competition
5. Next-Generation Sequencing (NGS) Market Assessment - by Offering
5.1. Overview
5.2. Sample Preparation
5.2.1. Kits & Reagents
5.2.1.1. Nucleic Acid Extraction and Amplification
5.2.1.2. Library Preparation
5.2.1.2.1. DNA Library Preparation
5.2.1.2.2. RNA Library Preparation
5.2.1.3. Quality Control
5.2.1.4. Other Kits & Reagents
5.2.2. NGS Workstations
5.3. Sequencing
5.3.1. NGS Systems
5.3.1.1. Sequencing by Synthesis
5.3.1.2. Ion Semiconductor Sequencing
5.3.1.3. Single-Molecule Real-Time Sequencing (SMRT)
5.3.1.4. DNA Nanoball (DNB) Sequencing
5.3.1.5. Other Technologies
5.3.2. Consumables
5.3.3. Services
5.4. Data Analysis/Bioinformatics
5.4.1. Software
5.4.1.1. Software Market, by Type
5.4.1.1.1. Data Analysis Software
5.4.1.1.2. Data Interpretation and Reporting Tools
5.4.1.1.3. Data Storage and Computing Tools
5.4.1.1.4. Laboratory Information Management Systems (LIMS)
5.4.1.2. Software Market, by Deployment Mode
5.4.1.2.1. Web and Cloud-Based
5.4.1.2.2. On-Premise
5.4.2. NGS Informatics Services
5.5. Commercial Sequencing/Outsourced Services
5.5.1. Targeted Sequencing Services
5.5.2. RNA Sequencing Services
5.5.3. De Novo Sequencing Services
5.5.4. Exome Sequencing Services
5.5.5. Chip Sequencing Services
5.5.6. Methyl Sequencing Services
5.5.7. Whole Genome Sequencing Services
5.5.8. Other Commercial Sequencing Services
6. Next-Generation Sequencing (NGS) Market Assessment — by Application
6.1. Overview
6.2. Research & Other Applications
6.2.1. Drug Discovery
6.2.2. Agriculture & Animal Research
6.2.3. Other Applications
6.3. Clinical Applications
6.3.1. Oncology
6.3.2. Reproductive Health
6.3.3. Infectious Diseases
6.3.4. Other Clinical Applications
7. Next-Generation Sequencing (NGS) Market Assessment — by End User
7.1. Overview
7.2. Pharmaceutical & Biotechnology Companies
7.3. Hospitals & Diagnostic Laboratories
7.4. Academic Institutes & Research Centers
7.5. Other End Users
8. Next-Generation Sequencing (NGS) Market Assessment — by Geography
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.5.1. Brazil
8.5.2. Mexico
8.5.3. Rest of Latin America (RoLATAM)
8.6. Middle East & Africa
9. Competition Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis (2023)
9.5.1. Instrument & Consumables
9.5.2. Data Analysis/Bioinformatics
9.5.3. Commercial Sequencing/Outsourced Services
9.5.4. NGS Workstations
10. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
10.1. Illumina, Inc.
10.2. Thermo Fisher Scientific Inc.
10.3. F. Hoffmann-La Roche Ltd
10.4. Eurofins Scientific Se
10.5. Beijing Genomics Institute (BGI)
10.6. Qiagen N.V.
10.7. Agilent Technologies, Inc.
10.8. Revvity, Inc.
10.9. Pacific Biosciences of California Inc.
10.10. Danaher Corporation
10.11. Oxford Nanopore Technologies Plc.
10.12. Tecan Group Ltd.
10.13. Hamilton Company
10.14. Hudson Robotics
10.15. LGC Limited
10.16. Eppendorf AG
10.17. Novogene Co., Ltd.
10.18. Dnastar, Inc.
10.19. Fabric Genomics, Inc.
10.20. MGI Tech Co., Ltd.
10.21. Quest Diagnostics Incorporated
(*Note: SWOT Analysis Provided for Top 5 Companies*)
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1 Global NGS Market: Impact Analysis of Market Dynamics (2024–2031)
Table 2 Global Estimated Number of New Cancer Cases, by Type (2020 Vs. 2030)
Table 3 Incidence of Common Genetic Disorders
Table 4 Major Genome Sequencing Projects, by Country
Table 5 Portable Sequencers Vs. Benchtop Sequencers
Table 6 NGS Instruments Price List
Table 7 NGS Consumables Price List
Table 8 Key NGS Service Providers’ Price List
Table 9 Regulatory Authorities Governing In Vitro Diagnostics & NGS Products, by Country/Region
Table 10 NGS Software: Standards and Compliance Guidelines
Table 11 NGS Informatics: Standards and Compliance Guidelines
Table 12 Global NGS Market, by Offering, 2022–2031 (USD Million)
Table 14 Global NGS Sample Preparation Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global NGS Sample Preparation Kits & Reagents Market, by Type, 2022–2031 USD Million)
Table 16 Global NGS Sample Preparation Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Nucleic Acid Extraction and Amplification Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 19 Global Library Preparation Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Global DNA Library Preparation Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 21 Global RNA Library Preparation Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Quality Control Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Other Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 24 Global NGS Workstations Market for NGS Library Preparation, by Country/Region, 2022–2031 (USD Million)
Table 25 Global Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 26 Global Sequencing Market, by Country/Region, 2022–2031 (USD Million)
Table 27 Global NGS Systems Market, by Technology, 2022–2031 (USD Million)
Table 28 Global NGS Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Sequencing by Synthesis Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 30 Major Applications of Ion Torrent Sequencing
Table 31 Global Ion Semi Conductor Sequencing Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Smrt Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 33 Global DNA Nanoball Sequencing Systems Market, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Other Technologies Market, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Services Market, by Country/Region, 2022–2031 (USD Million)
Table 37 Global Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 38 Global Data Analysis/Bioinformatics Market, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Data Analysis/Bioinformatics Software Market, by Country/Region, 2022–2031 (USD Million)
Table 40 Global Data Analysis/Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 41 Global Data Analysis Software Market, by Country/Region, 2022-2031 (USD Million)
Table 42 Global Data Interpretation and Reporting Tools Market, by Country/Region, 2022-2031 (USD Million)
Table 43 Global Data Storage and Computing Tools Market, by Country/Region, 2022-2031 (USD Million)
Table 44 Global Laboratory Information Management Systems (LIMS) Market by Country/Region, 2022-2031 (USD Million)
Table 45 Global Data Analysis/Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 46 Global Web and Cloud-Based Data/Analysis and Bioinformatics Market by Country/Region, 2022-2031 (USD Million)
Table 47 Global On-Premise Data/Analysis and Bioinformatics Market by Country/Region, 2022-2031 (USD Million)
Table 48 Global NGS Informatics Services Market by Country/Region, 2022-2031 (USD Million)
Table 49 Global NGS Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 50 Global Commercial Sequencing/Outsourced Services Market by Country/Region, 2022-2031 (USD Million)
Table 51 Global Targeted Sequencing Services Market by Country/Region, 2022-2031 (USD Million)
Table 52 Global RNA Sequencing Services Market by Country/Region, 2022-2031 (USD Million)
Table 53 Global De Novo Sequencing Services Market by Country/Region, 2022-2031 (USD Million)
Table 54 Global Exome Sequencing Services Market by Country/Region, 2022-2031 (USD Million)
Table 55 Global Chip Sequencing Services Market by Country/Region, 2022-2031 (USD Million)
Table 56 Global Methylation Sequencing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 57 Global Whole Genome Sequencing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 58 Global Other Commercial Sequencing Services Market, by Country/Region, 2022-2031 (USD Million)
Table 59 Global Next-Generation Sequencing (NGS) Market, by Application, 2022–2031 (USD Million)
Table 60 Global NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 61 Global NGS Market for Research & Other Applications by Country/Region, 2022–2031 (USD Million)
Table 62 Global NGS Market for Drug Discovery, by Country/Region, 2022–2031 (USD Million)
Table 63 Global NGS Market for Agriculture & Animal Research, by Country/Region, 2022–2031 (USD Million)
Table 64 Global NGS Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 65 Global NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 66 Global NGS Market for Clinical Applications, by Country/Region, 2022–2031 (USD Million)
Table 67 Currently Available Targeted Therapies and Corresponding Biomarkers
Table 68 Global NGS Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 69 Global NGS Market for Reproductive Health, by Country/Region, 2022–2031 (USD Million)
Table 70 Number of New HIV Infections, by Region, 2022
Table 71 Global NGS Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 72 Global NGS Market for Other Clinical Applications, by Country/Region, 2022–2031 (USD Million)
Table 73 Global Next-Generation Sequencing Market, by End User, 2022–2031 (USD Million)
Table 74 Pharmaceutical Spending in Major Countries
Table 75 Global Next-Generation Sequencing Market for Pharmaceutical & Biotechnology Companies, by Offering, 2022–2031 (USD Million)
Table 76 Global Next-Generation Sequencing Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 77 Global Next-Generation Sequencing Market for Hospitals & Diagnostic Laboratories, by Offering, 2022–2031 (USD Million)
Table 78 Global Next-Generation Sequencing Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 79 Global Next-Generation Sequencing Market for Academic Institutes & Research Centers, by Offering, 2022–2031 (USD Million)
Table 80 Global Next-Generation Sequencing Market for Academic Institutes & Research Centers, by Country/Region, 2022–2031 (USD Million)
Table 81 Global Next-Generation Sequencing Market for Other End Users, by Offering, 2022–2031 (USD Million)
Table 82 Global Next-Generation Sequencing Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 83 Global NGS Market, by Country/Region, 2022–2031 (USD Million)
Table 84 North America: NGS Market, by Country, 2022–2031 (USD Million)
Table 85 North America: NGS Market, by Offering, 2022–2031 (USD Million)
Table 86 North America: Sample Preparation Market, by Type, 2022–2031 (USD Million)
Table 87 North America: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 88 North America: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 89 North America: Sequencing Market, by Type, 2022–2031 (USD Million)
Table 90 North America: Sequencing Systems Market, by Technology, 2022–2031 (USD Million)
Table 91 North America: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 92 North America: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 93 North America: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 94 North America: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 95 North America: NGS Market, by Application, 2022–2031 (USD Million)
Table 96 North America: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 97 North America: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 98 North America: NGS Market, by End User, 2022–2031 (USD Million)
Table 99 U.S.: NGS Market, by Offering, 2022–2031 (USD Million)
Table 100 U.S.: Sample Preparation Market, by Type, 2022–2031 (USD Million)
Table 101 U.S.: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 102 U.S.: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 103 U.S.: Sequencing Market, by Type, 2022–2031 (USD Million)
Table 104 U.S.: Sequencing Systems Market, by Technology, 2022–2031 (USD Million)
Table 105 U.S.: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 106 U.S.: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 107 U.S.: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 108 U.S.: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 109 U.S.: NGS Market, by Application, 2022–2031 (USD Million)
Table 110 U.S.: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 111 U.S.: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 112 U.S.: NGS Market, by End User, 2022–2031 (USD Million)
Table 113 Canada: NGS Market, by Offering, 2022–2031 (USD Million)
Table 114 Canada: Sample Preparation Market, by Type, 2022–2031 (USD Million)
Table 115 Canada: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 116 Canada: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 117 Canada: Sequencing Market, by Type, 2022–2031 (USD Million)
Table 118 Canada: Sequencing Systems Market, by Technology, 2022–2031 (USD Million)
Table 119 Canada: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 120 Canada: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 121 Canada: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 122 Canada: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 123 Canada: NGS Market, by Application, 2022–2031 (USD Million)
Table 124 Canada: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 125 Canada: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 126 Canada: NGS Market, by End User, 2022–2031 (USD Million)
Table 127 Europe: NGS Market, by Country/Region, 2022–2031 (USD Million)
Table 128 Europe: NGS Market, by Offering, 2022–2031 (USD Million)
Table 129 Europe: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 130 Europe: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 131 Europe: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 132 Europe: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 133 Europe: NGS Market, by Technology, 2022–2031 (USD Million)
Table 134 Europe: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 135 Europe: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 136 Europe: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 137 Europe: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 138 Europe: NGS Market, by Application, 2022–2031 (USD Million)
Table 139 Europe: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 140 Europe: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 141 Europe: NGS Market, by End User, 2022–2031 (USD Million)
Table 142 Germany: NGS Market, by Offering, 2022–2031 (USD Million)
Table 143 Germany: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 144 Germany: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 145 Germany: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 146 Germany: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 147 Germany: NGS Market, by Technology, 2022–2031 (USD Million)
Table 148 Germany: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 149 Germany: NGS Bioinformatics Software Market, by Offering, 2022–2031 (USD Million)
Table 150 Germany: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 151 Germany: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 152 Germany: NGS Market, by Application, 2022–2031 (USD Million)
Table 153 Germany: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 154 Germany: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 155 Germany: NGS Market, by End User, 2022–2031 (USD Million)
Table 156 France: NGS Market, by Offering, 2022–2031 (USD Million)
Table 157 France: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 158 France: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 159 France: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 160 France: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 161 France: NGS Market, by Technology, 2022–2031 (USD Million)
Table 162 France: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 163 France: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 164 France: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 165 France: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 166 France: NGS Market, by Application, 2022–2031 (USD Million)
Table 167 France: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 168 France: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 169 France: NGS Market, by End User, 2022–2031 (USD Million)
Table 170 U.K.: NGS Market, by Offering, 2022–2031 (USD Million)
Table 171 U.K.: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 172 U.K.: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 173 U.K.: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 174 U.K.: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 175 U.K.: NGS Market, by Technology, 2022–2031 (USD Million)
Table 176 U.K.: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 177 U.K.: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 178 U.K.: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 179 U.K.: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 180 U.K.: NGS Market, by Application, 2022–2031 (USD Million)
Table 181 U.K.: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 182 U.K.: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 183 U.K.: NGS Market, by End User, 2022–2031 (USD Million)
Table 184 Italy: NGS Market, by Offering, 2022–2031 (USD Million)
Table 185 Italy: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 186 Italy: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 187 Italy: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 188 Italy: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 189 Italy: NGS Market, by Technology, 2022–2031 (USD Million)
Table 190 Italy: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 191 Italy: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 192 Italy: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 193 Italy: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 194 Italy: NGS Market, by Application, 2022–2031 (USD Million)
Table 195 Italy: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 196 Italy: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 197 Italy: NGS Market, by End User, 2022–2031 (USD Million)
Table 198 Spain: NGS Market, by Offering, 2022–2031 (USD Million)
Table 199 Spain: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 200 Spain: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 201 Spain: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 202 Spain: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 203 Spain: NGS Market, by Technology, 2022–2031 (USD Million)
Table 204 Spain: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 205 Spain: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 206 Spain: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 207 Spain: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 208 Spain: NGS Market, by Application, 2022–2031 (USD Million)
Table 209 Spain: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 210 Spain: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 211 Spain: NGS Market, by End User, 2022–2031 (USD Million)
Table 212 Roe: Estimated Number of New Cancer Cases, by Country, 2022 Vs. 2030
Table 213 Rest of Europe: NGS Market, by Offering, 2022–2031 (USD Million)
Table 214 Rest of Europe: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 215 Rest of Europe: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 216 Rest of Europe: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 217 Rest of Europe: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 218 Rest of Europe: Sequencing Systems Market, by Technology, 2022–2031 (USD Million)
Table 219 Rest of Europe: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 220 Rest of Europe: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 221 Rest of Europe: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 222 Rest of Europe: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 223 Rest of Europe: NGS Market, by Application, 2022–2031 (USD Million)
Table 224 Rest of Europe: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 225 Rest of Europe: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 226 Rest of Europe: NGS Market, by End User, 2022–2031 (USD Million)
Table 227 Asia-Pacific: NGS Market, by Country/Region, 2022–2031 (USD Million)
Table 228 Asia-Pacific: NGS Market, by Offering, 2022–2031 (USD Million)
Table 229 Asia-Pacific: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 230 Asia-Pacific: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 231 Asia-Pacific: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 232 Asia-Pacific: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 233 Asia-Pacific: NGS Market, by Technology, 2022–2031 (USD Million)
Table 234 Asia-Pacific: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 235 Asia-Pacific: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 236 Asia-Pacific: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 237 Asia-Pacific: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 238 Asia-Pacific: NGS Market, by Application, 2022–2031 (USD Million)
Table 239 Asia-Pacific: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 240 Asia-Pacific: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 241 Asia-Pacific: NGS Market, by End User, 2022–2031 (USD Million)
Table 242 China: NGS Market, by Offering, 2022–2031 (USD Million)
Table 243 China: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 244 China: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 245 China: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 246 China: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 247 China: NGS Market, by Technology, 2022–2031 (USD Million)
Table 248 China: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 249 China: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 250 China: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 251 China: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 252 China: NGS Market, by Application, 2022–2031 (USD Million)
Table 253 China: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 254 China: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 255 China: NGS Market, by End User, 2022–2031 (USD Million)
Table 256 Japan: NGS Market, by Offering, 2022–2031 (USD Million)
Table 257 Japan: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 258 Japan: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 259 Japan: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 260 Japan: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 261 Japan: NGS Market, by Technology, 2022–2031 (USD Million)
Table 262 Japan: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 263 Japan: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 264 Japan: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 265 Japan: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 266 Japan: NGS Market, by Application, 2022–2031 (USD Million)
Table 267 Japan: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 268 Japan: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 269 Japan: NGS Market, by End User, 2022–2031 (USD Million)
Table 270 India: NGS Market, by Offering, 2022–2031 (USD Million)
Table 271 India: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 272 India: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 273 India: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 274 India: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 275 India: Sequencing Systems Market, by Technology, 2022–2031 (USD Million)
Table 276 India: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 277 India: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 278 India: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 279 India: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 280 India: NGS Market, by Application, 2022–2031 (USD Million)
Table 281 India: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 282 India: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 283 India: NGS Market, by End User, 2022–2031 (USD Million)
Table 284 Rest of Asia-Pacific: Estimated Number of New Cancer Cases, by Country, 2022 Vs. 2030
Table 285 Rest of Asia-Pacific: NGS Market, by Offering, 2022–2031 (USD Million)
Table 286 Rest of Asia-Pacific: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 287 Rest of Asia-Pacific: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 288 Rest of Asia-Pacific: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 289 Rest of Asia-Pacific: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 290 Rest of Asia-Pacific: Sequencing Systems Market, by Technology, 2022–2031 (USD Million)
Table 291 Rest of Asia-Pacific: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 292 Rest of Asia-Pacific: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 293 Rest of Asia-Pacific: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 294 Rest of Asia-Pacific: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 295 Rest of Asia-Pacific: NGS Market, by Application, 2022–2031 (USD Million)
Table 296 Rest of Asia-Pacific: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 297 Rest of Asia-Pacific: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 298 Rest of Asia-Pacific: NGS Market, by End User, 2022–2031 (USD Million)
Table 299 Latin America: NGS Market, by Country/Region, 2022–2031 (USD Million)
Table 300 Latin America: NGS Market, by Offering, 2022–2031 (USD Million)
Table 301 Latin America: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 302 Latin America: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 303 Latin America: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 304 Latin America: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 305 Latin America: NGS Market, by Technology, 2022–2031 (USD Million)
Table 306 Latin America: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 307 Latin America: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 308 Latin America: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 309 Latin America: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 310 Latin America: NGS Market, by Application, 2022–2031 (USD Million)
Table 311 Latin America: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 312 Latin America: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 313 Latin America: NGS Market, by End User, 2022–2031 (USD Million)
Table 314 Brazil: NGS Market, by Offering, 2022–2031 (USD Million)
Table 315 Brazil: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 316 Brazil: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 317 Brazil: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 318 Brazil: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 319 Brazil: NGS Market, by Technology, 2022–2031 (USD Million)
Table 320 Brazil: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 321 Brazil: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 322 Brazil: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 323 Brazil: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 324 Brazil: NGS Market, by Application, 2022–2031 (USD Million)
Table 325 Brazil: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 326 Brazil: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 327 Brazil: NGS Market, by End User, 2022–2031 (USD Million)
Table 328 Mexico: NGS Market, by Offering, 2022–2031 (USD Million)
Table 329 Mexico: Sample Preparation Market, by Type, 2022–2031 (USD Million)
Table 330 Mexico: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 331 Mexico: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 332 Mexico: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 333 Mexico: NGS Market, by Technology, 2022–2031 (USD Million)
Table 334 Mexico: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 335 Mexico: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 336 Mexico: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 337 Mexico: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 338 Mexico: NGS Market, by Application, 2022–2031 (USD Million)
Table 339 Mexico: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 340 Mexico: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 341 Mexico: NGS Market, by End User, 2022–2031 (USD Million)
Table 342 Rest of Latin America: NGS Market, by Offering, 2022–2031 (USD Million)
Table 343 Rest of Latin America: Sample Preparation Market, by Type, 2022–2031 (USD Million)
Table 344 Rest of Latin America: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 345 Rest of Latin America: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 346 Rest of Latin America: Sequencing Market, by Type, 2022–2031 (USD Million)
Table 347 Rest of Latin America: NGS Market, by Technology, 2022–2031 (USD Million)
Table 348 Rest of Latin America: Data Analysis/Bioinformatics Market, by Type, 2022–2031 (USD Million)
Table 349 Rest of Latin America: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 350 Rest of Latin America: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 351 Rest of Latin America: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 352 Rest of Latin America: NGS Market, by Application, 2022–2031 (USD Million)
Table 353 Rest of Latin America: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 354 Rest of Latin America: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 355 Rest of Latin America: NGS Market, by End User, 2022–2031 (USD Million)
Table 356 Middle East & Africa: NGS Market, by Offering, 2022–2031 (USD Million)
Table 357 Middle East & Africa: Sample Preparation Market, by Offering, 2022–2031 (USD Million)
Table 358 Middle East & Africa: Sample Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 359 Middle East & Africa: Library Preparation Kits & Reagents Market, by Type, 2022–2031 (USD Million)
Table 360 Middle East & Africa: Sequencing Market, by Offering, 2022–2031 (USD Million)
Table 361 Middle East & Africa: NGS Market, by Technology, 2022–2031 (USD Million)
Table 362 Middle East & Africa: Data Analysis/Bioinformatics Market, by Offering, 2022–2031 (USD Million)
Table 363 Middle East & Africa: NGS Bioinformatics Software Market, by Type, 2022–2031 (USD Million)
Table 364 Middle East & Africa: NGS Bioinformatics Software Market, by Deployment Mode, 2022–2031 (USD Million)
Table 365 Middle East & Africa: Commercial Sequencing/Outsourced Services Market, by Type, 2022–2031 (USD Million)
Table 366 Middle East & Africa: NGS Market, by Application, 2022–2031 (USD Million)
Table 367 Middle East & Africa: NGS Market for Research & Other Applications, by Type, 2022–2031 (USD Million)
Table 368 Middle East & Africa: NGS Market for Clinical Applications, by Type, 2022–2031 (USD Million)
Table 369 Middle East & Africa: NGS Market, by End User, 2022–2031 (USD Million)
Table 370 Recent Developments, by Company, 2021-2024
Table 371 Illumina IVD Instrument Specification
Table 372 Illumina Informatics Options for Dx Instruments
Table 373 Supported IVD Assays
Table 374 Supported Clinical Research Panels in Ruo Mode
Table 375 IVD Instrument Comparison Table
Table 376 Key Specifications (Dx Mode)
Table 377 Production-Scale Sequencers Specifications
Table 378 Production-Scale Sequencers - Key Applications and Methods
Table 379 Illumina, Inc. (U.S.): NGS Systems Installed Base & New Installations In 2022
Table 380 Illumina, Inc. (U.S.): NGS Systems Installed Base & New Installations In 2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Next-Generation Sequencing Market, By Offering, 2024 Vs. 2031 (USD Million)
Figure 8 Global Next-Generation Sequencing Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 9 Global Next-Generation Sequencing Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 10 Global Next-Generation Sequencing Market, By Geography, 2024 Vs. 2031 (USD Million)
Figure 11 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 12 U.S.: Percentage of Personalized Medicine Approvals Among Total FDA Approvals, 2015-2022 (%)
Figure 13 Genome Sequencing Costs, 2016-2022 (USD)
Figure 14 USFDA Regulatory Pathways for IVD Kits
Figure 15 Eu Regulatory Pathway - IVDR 2017/746
Figure 16 China: Medical Device Classification and Pre-Market Requirements for NGS Instruments
Figure 17 Porter's Five Forces Analysis
Figure 18 Global NGS Market, By Offering, 2024 Vs 2031 (USD Million)
Figure 19 Steps of Sample Preparation in A Typical NGS Workflow
Figure 20 Global: Estimated Number of New Cancer Cases, 2022 - 2030
Figure 21 Global Next-Generation Sequencing (NGS) Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 22 U.S.: New Molecular Entity (NME) Approvals, 2011–2022
Figure 23 Estimated Number of New Cancer Cases, 2020–2040 (In Million)
Figure 24 Global Next-Generation Sequencing Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 25 Global Pharmaceutical R&D Spending, 2014–2028 (USD Billion)
Figure 26 NGS Market Assessment, By Region, 2024 Vs. 2031 (USD Million)
Figure 27 North America: Per Capita Healthcare Expenditure, 2017-2022
Figure 28 North America: NGS Market Snapshot
Figure 29 Europe: Pharmaceutical R&D Expenditure Annual Growth Rate (%)
Figure 30 Europe: NGS Market Snapshot
Figure 31 Italy: Number of Biotechnology and Biotechnology R&D-Dedicated Firms, 2014-2022
Figure 32 Spain Pharmaceutical R&D Expenditure, 2018-2022 (USD Million)
Figure 33 Rest of Europe: Pharmaceutical R&D Expenditure, 2021 (USD Million)
Figure 34 Asia-Pacific: NGS Market Snapshot
Figure 35 Japan: Pharmaceutical Industry R&D Expenditure, 2017-2022 (USD Million)
Figure 36 Japan: Number of New Molecular Entities Approved, 2017-2022
Figure 37 Latin America: NGS Market Snapshot
Figure 38 Number of Active Life Science Companies in Israel (2017-2022)
Figure 39 Key Growth Strategies Adopted by Leading Players, 2021– 2024
Figure 40 Next-Generation Sequencing Market: Competitive Benchmarking by Offering
Figure 41 Next-Generation Sequencing Market: Competitive Benchmarking, by Region
Figure 42 Competitive Dashboard: Next-Generation Sequencing Market
Figure 43 Illumina, Inc.: Financial Snapshot (2023)
Figure 44 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 45 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
Figure 46 Eurofins Scientific Se: Financial Overview (2023)
Figure 47 Beijing Genomics Institute (BGI): Financial Snapshot (2023)
Figure 48 Qiagen N.V: Financial Snapshot (2023)
Figure 49 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 50 Revvity, Inc.: Financial Snapshot (2023)
Figure 51 Pacific Biosciences of California Inc.: Financial Snapshot (2023)
Figure 52 Danaher Corporation: Financial Snapshot (2023)
Figure 53 Oxford Nanopore Technologies Plc.: Financial Snapshot (2023)
Figure 54 Tecan Group Ltd.: Financial Snapshot (2023)
Figure 55 LGC Limited: Financial Overview (2023)
Figure 56 Eppendorf Ag: Financial Overview (2023)
Figure 57 Novogene Co., Ltd.: Financial Overview (2023)
Figure 58 MGI Tech Co., Ltd.: Financial Snapshot (2023)
Figure 59 Quest Diagnostics Incorporated: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
North America NGS Automation Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Europe NGS Automation Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Europe NGS Market - Opportunity Analysis and Industry Forecasts (2024-2030)
Published Date: Jul-2024
North America NGS Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific NGS Automation Market - Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Feb-2024
